Stephan M. Ensminger

TL;DR: This consensus document is based on best evidence and clinical consensus derived from critical analysis of available information pertaining to angiography, intravascular ultrasound imaging, microvascular function, cardiac allograft histology, circulating immune markers, non-invasive imaging tests, and gene-based and protein-based biomarkers.

TL;DR: A clinical definition for AMR (cardiac dysfunction and/or circulating donor-specific antibody) was no longer believed to be required due to recent publications demonstrating that asymptomatic (no cardiac dysfunction) biopsy-proven AMR is associated with subsequent greater mortality and greater development of cardiac allograft vasculopathy.

TL;DR: Transapical JenaValve™ implantation was safe and effective in the treatment of severe AS in elderly patients at high risk for conventional heart surgery and prevented ostial coronary impairment.

TL;DR: New embolic ischemic cerebral insults are detected in 68% of patients after transapical aortic valve implantation, and in 17 patients (68%), new cerebral lesions could be detected, whereas 8 patients showed no new cerebral insults.

TL;DR: Data from experiments in mice and men revealed various intersection points between thrombosis, hemostasis, and inflammation, which are addressed and discussed in this research and will potentially offer novel opportunities for therapeutic intervention in diseases featuring platelet abundance.